Arg-leu-tyr-glu suppresses retinal endothelial permeability and choroidal neovascularization by inhibiting the VEGF receptor 2 signaling pathway

Wonjin Park, Yi Yong Baek, Joohwan Kim, Dong Hyun Jo, Seunghwan Choi, Jin Hyoung Kim, Taesam Kim, Suji Kim, Minsik Park, Ji Yoon Kim, Moo Ho Won, Kwon Soo Ha, Jeong Hun Kim, Young Guen Kwon, Young Myeong Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) plays a pivotal role in pathologic ocular neovascularization and vascular leakage via activation of VEGF receptor 2 (VEGFR2). This study was undertaken to evaluate the therapeutic mechanisms and effects of the tetrapeptide Arg-Leu-Tyr-Glu (RLYE), a VEGFR2 inhibitor, in the development of vascular permeability and choroidal neovascularization (CNV). In cultured human retinal microvascular endothelial cells (HRMECs), treatment with RLYE blocked VEGF-Ainduced phosphorylation of VEGFR2, Akt, ERK, and endothelial nitric oxide synthase (eNOS), leading to suppression of VEGFA- mediated hyper-production of NO. Treatment with RLYE also inhibited VEGF-A-stimulated angiogenic processes (migration, proliferation, and tube formation) and the hyperpermeability of HRMECs, in addition to attenuating VEGF-A-induced angiogenesis and vascular permeability in mice. The anti-vascular permeability activity of RLYE was correlated with enhanced stability and positioning of the junction proteins VE-cadherin, β-catenin, claudin-5, and ZO-1, critical components of the cortical actin ring structure and retinal endothelial barrier, at the boundary between HRMECs stimulated with VEGF-A. Furthermore, intravitreally injected RLYE bound to retinal microvascular endothelium and inhibited laser-induced CNV in mice. These findings suggest that RLYE has potential as a therapeutic drug for the treatment of CNV by preventing VEGFR2-mediated vascular leakage and angiogenesis.

Original languageEnglish
Pages (from-to)474-483
Number of pages10
JournalBiomolecules and Therapeutics
Volume27
Issue number5
DOIs
Publication statusPublished - 2019 Sep

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Park, W., Baek, Y. Y., Kim, J., Jo, D. H., Choi, S., Kim, J. H., Kim, T., Kim, S., Park, M., Kim, J. Y., Won, M. H., Ha, K. S., Kim, J. H., Kwon, Y. G., & Kim, Y. M. (2019). Arg-leu-tyr-glu suppresses retinal endothelial permeability and choroidal neovascularization by inhibiting the VEGF receptor 2 signaling pathway. Biomolecules and Therapeutics, 27(5), 474-483. https://doi.org/10.4062/biomolther.2019.041